Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julie Miller is active.

Publication


Featured researches published by Julie Miller.


Infection and Immunity | 2002

A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection

Helen C. Flick-Smith; Nicola Walker; Paula Gibson; Helen L. Bullifent; Sarah Hayward; Julie Miller; Richard W. Titball; E. Diane Williamson

ABSTRACT The immunogenicity and protective efficacy of overlapping regions of the protective antigen (PA) polypeptide, cloned and expressed as glutathione S-transferase fusion proteins, have been assessed. Results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of PA.


Infection and Immunity | 2002

Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice

Helen C. Flick-Smith; Jim E. Eyles; Richard Hebdon; Emma Waters; Richard J. Beedham; Tony J. Stagg; Julie Miller; H. Oya Alpar; Les Baillie; E. Diane Williamson

ABSTRACT Existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce protective immunity. This requires trained personnel and is not the optimum route for stimulating a mucosal immune response. Microencapsulation of vaccine antigens offers a number of advantages over traditional vaccine formulations, including stability without refrigeration and the potential for utilizing less invasive routes of administration. Recombinant protective antigen (rPA), the dominant antigen for protection against anthrax infection, was encapsulated in poly-l-lactide 100-kDa microspheres. Alternatively, rPA was loosely attached to the surfaces of microspheres by lyophilization. All of the microspheric formulations were administered to A/J mice with a two-dose schedule by either the intramuscular route, the intranasal route, or a combination of these two routes, and immunogenicity and protective efficacy were assessed. An intramuscular priming immunization followed by either an intramuscular or intranasal boost gave optimum anti-rPA immunoglobulin G titers. Despite differences in rPA-specific antibody titers, all immunized mice survived an injected challenge consisting of 103 median lethal doses of Bacillus anthracis STI spores. Immunization with microencapsulated and microsphere-associated formulations of rPA also protected against aerosol challenge with 30 median lethal doses of STI spores. These results show that rPA can be encapsulated and surface bound to polymeric microspheres without impairing its immunogenicity and also that mucosal or parenteral administration of microspheric formulations of rPA efficiently protects mice against both injected and aerosol challenges with B. anthracis spores. Microspheric formulations of rPA could represent the next generation of anthrax vaccines, which could require fewer doses because they are more potent, are less reactogenic than currently available human anthrax vaccines, and could be self-administered without injection.


Biophysical Journal | 2001

Probing Molecular Interactions in Intact Antibody: Antigen Complexes, an Electrospray Time-of-Flight Mass Spectrometry Approach

Mark A. Tito; Julie Miller; Nicola Walker; Kate F. Griffin; E. Diane Williamson; Dominique Despeyroux-Hill; Richard W. Titball; Carol V. Robinson

Using a combination of nanoflow-electrospray ionization and time-of-flight mass spectrometry we have analyzed the oligomeric state of the recombinant V antigen from Yersinia pestis, the causative agent of plague. The mass spectrometry results show that at pH 6.8 the V antigen in solution exists predominantly as a dimer and a weakly associated tetramer. A monoclonal antibody 7.3, raised against the V antigen, gave rise to mass spectra containing a series of well-resolved charge states at m/z 6000. After addition of aliquots of solution containing V antigen in substoichiometric and molar equivalents, the spectra revealed that two molecules of the V antigen bind to the antibody. Collision-induced dissociation of the antibody-antigen complex results in the selective release of the dimer from the complex supporting the proposed 1:2 antibody:antigen stoichiometry. Control experiments with the recombinant F1 antigen, also from Yersinia pestis, establish that the antibody is specific for the V antigen because no complex with F1 was detected even in the presence of a 10-fold molar excess of F1 antigen. More generally this work demonstrates a rapid means of assessing antigen subunit interactions as well as the stoichiometry and specificity of binding in antibody-antigen complexes.


Journal of Applied Microbiology | 1999

Presentation of protective antigen to the mouse immune system: immune sequelae

Ethel Diane Williamson; R. J. Beedham; A.M. Bennett; S. D. Perkins; Julie Miller; Les Baillie

Protective antigen (PA), the major protective component of the existing vaccine, is a potent immunogen. Protective antigen in alhydrogel induced a high serum IgG titre (> log10 4) in both the C57B16 and Balb/c mouse and the predominant subclass of antibody induced was IgG1, indicating that the response to PA was predominantly Th2 directed. When plasmid DNA encoding PA was used to immunize the Balb/c mouse, a low serum IgG titre was detected (≤log10 1), which was slightly increased by boosting with plasmid DNA. However, when mice immunized with plasmid DNA were later boosted with rPA, a significant and rapid increase in titre (up to threefold) was observed. Priming mice with PA‐encoding plasmid DNA may be a mechanism of enhancing and accelerating the immune response to PA.


Vaccine | 2002

Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague.

E.D. Williamson; Alice M. Bennett; Stuart D. Perkins; R.J Beedham; Julie Miller; L.W.J Baillie

The protective antigen (PA) of Bacillus anthracis and the V antigen of Yersinia pestis are potent immunogens and candidate vaccine sub-units. When plasmid DNA encoding either PA or V antigen was used to immunise the Balb/c mouse, a low serum IgG titre was detected (log (10)1.0 or less) which was slightly increased by boosting with plasmid DNA. However, when mice immunised with plasmid DNA were later boosted with the respective recombinant protein, a significant increase in titre (up to 100-fold) was observed. Mice primed with a combination of each plasmid and boosted with a combination of the recombinant proteins, were fully protected (6/6) against challenge with Y. pestis. This compared favourably with mice primed only with plasmid DNA encoding the V antigen and boosted with rV, which were partially protected (3/6) against homologous challenge or with mice primed and boosted with plasmid DNA encoding the V antigen which were poorly protected (1/6). Combined immunisation with the two plasmid DNA constructs followed by boosting with a combination of the encoded recombinant proteins enhanced the protective immune response to Y. pestis compared with priming only with plasmid DNA encoding the V antigen and boosting with rV. This enhancement may be due to the effect of CpG motifs known to be present in the plasmid DNA construct encoding PA.


Biochemical and Biophysical Research Communications | 1992

The importance of arginine 102 for the substrate specificity of Escherichia coli malate dehydrogenase

David J. Nicholls; Julie Miller; Michael D. Scawen; Anthony R. Clarke; J. John Holbrook; Tony Atkinson; Christopher R. Goward

The malate dehydrogenase from Escherichia coli has been specifically altered at a single amino acid residue by using site-directed mutagenesis. The conserved Arg residue at amino acid position 102 in the putative substrate binding site was replaced with a Gln residue. The result was the loss of the high degree of specificity for oxaloacetate. The difference in relative binding energy for oxaloacetate amounted to about 7 kcal/mol and a difference in specificity between oxaloacetate and pyruvate of 8 orders of magnitude between the wild-type and mutant enzymes. These differences may be explained by the large hydration potential of Arg and the formation of a salt bridge with a carboxylate group of oxaloacetate.


Journal of Biological Chemistry | 1999

Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphatase alpha.

Caroline H. Arnott; Elizabeth M. Sale; Julie Miller; Graham J. Sale

The protein-tyrosine phosphatase PTPα has been proposed to play an important role in controlling the dephosphorylation of a number of key signaling proteins and in regulating insulin signaling. To examine the potential cellular functions and physiological substrates of PTPα, a potent phosphorothioate oligonucleotide-based antisense strategy was developed that specifically depleted endogenous PTPα from 3T3-L1 adipocytes. The antisense probe, αAS1, achieved PTPα depletion levels normally of ≥85% and which varied up to levels where PTPα was not detected at all. Elimination of PTPα by 85% inhibited c-Src activity by 80%. Abolishing PTPα to levels undetected did not alter the tyrosine dephosphorylation of the insulin receptor or insulin receptor substrate proteins. Moreover, the ability of insulin to activate ERK2 or to stimulate DNA synthesis was not altered by αAS1. It is concluded that endogenous PTPα is a key regulator of c-Src activity in 3T3-L1 adipocytes and that PTPα is not required for the dephosphorylation of the insulin receptor or the insulin receptor substrate proteins or for the regulation of several downstream insulin signaling events in 3T3-L1 adipocytes. Finally, the development of the antisense probe, αAS1, provides an important molecular tool of general applicability for further dissecting the roles and precise targets of endogenous PTPα.


Infection and Immunity | 2006

Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation.

David A. Chalton; Julie A. Musson; Helen C. Flick-Smith; Nicola Walker; Alistair McGregor; Heather K. Lamb; E. Diane Williamson; Julie Miller; John H. Robinson; Jeremy H. Lakey

ABSTRACT Caf1, a chaperone-usher protein from Yersinia pestis, is a major protective antigen in the development of subunit vaccines against plague. However, recombinant Caf1 forms polymers of indeterminate size. We report the conversion of Caf1 from a polymer to a monomer by circular permutation of the gene. Biophysical evaluation confirmed that the engineered Caf1 was a folded monomer. We compared the immunogenicity of the engineered monomer with polymeric Caf1 in antigen presentation assays to CD4 T-cell hybridomas in vitro, as well as in the induction of antibody responses and protection against subcutaneous challenge with Y. pestis in vivo. In C57BL/6 mice, for which the major H-2b-restricted immunodominant CD4 T-cell epitopes were intact in the engineered monomer, immunogenicity and protective efficacy were preserved, although antibody titers were decreased 10-fold. Disruption of an H-2d-restricted immunodominant CD4 T-cell epitope during circular permutation resulted in a compromised T-cell response, a low postvaccination antibody titer, and a lack of protection of BALB/c mice. The use of circular permutation in vaccine design has not been reported previously.


International Journal of Medical Microbiology | 2000

Opening of the active site of Clostridium perfringens α-toxin may be triggered by membrane binding

Richard W. Titball; Claire E. Naylor; Julie Miller; David S. Moss; Ajit K. Basak

On the basis of amino acid sequence homologies with other phospholipases C, the alpha-toxin of Clostridium perfringens was predicted to be a two-domain protein. Using truncated forms of alpha-toxin the phospholipase C active site was shown to be located in the amino-terminal domain. Crystallographic studies have confirmed this organisation and have also revealed that the carboxy-terminal domain is structurally similar to the phospholipid-binding domains in eukaryotic proteins. This information has been used to devise a model predicting how alpha-toxin interacts with membranes via calcium-mediated recognition of phospholipid head groups and the interaction of hydrophobic amino acids with the phospholipid tail group. The binding of alpha-toxin to membranes appears to result in the opening of the active site allowing hydrolysis of membrane phospholipids.


Protein Science | 2008

Macromolecular organization of the Yersinia pestis capsular F1 antigen: Insights from time‐of‐flight mass spectrometry

Mark A. Tito; Julie Miller; Kate F. Griffin; E. Diane Williamson; Richard W. Titball; Carol V. Robinson

Mass spectrometry has been used to examine the subunit interactions in the capsular F1 antigen from Yersinia pestis, the causative agent of the plague. Introducing the sample using nanoflow electrospray from solution conditions in which the protein remains in its native state and applying collisional cooling to minimize the internal energy of the ions, multiple subunit interactions have been maintained. This methodology revealed assemblies of the F1 antigen that correspond in mass to both 7‐mers and 14‐mers, consistent with interaction of two seven‐membered units. The difference between the calculated masses and those measured experimentally for these higher‐order oligomers was found to increase proportionately with the size of the complex. This is consistent with a solvent‐filled central cavity maintained on association of the 7‐mer to the 14‐mer. The charge states of the ions show that an average of one and four surface accessible basic side‐chains are involved in maintaining the interactions between the 7‐mer units and neighboring subunits, respectively. Taken together, these findings provide new information about the stoichiometry and packing of the subunits involved in the assembly of the capsular antigen structure. More generally, the data show that the symmetry and packing of macromolecular complexes can be determined solely from mass spectrometry, without any prior knowledge of higher order structure

Collaboration


Dive into the Julie Miller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicola Walker

Defence Science and Technology Laboratory

View shared research outputs
Top Co-Authors

Avatar

E. Diane Williamson

Defence Science and Technology Laboratory

View shared research outputs
Top Co-Authors

Avatar

Helen C. Flick-Smith

Defence Science and Technology Laboratory

View shared research outputs
Top Co-Authors

Avatar

Helen L. Bullifent

Defence Science and Technology Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge